Drug majors sniff around Denmark's Ascendis, which has been up for sale; Cognis sells out to BASF
Danish early-stage biotechnology company Ascendis Pharma is up for sale, according to a person familiar with the matter reported by the Wall Street Journal. The auction has drawn interest from a handful of health care heavyweights such as French drug major Sanofi-Aventis and US biotech firm Amgen, but the WSJ said none of the companies were open to comment at the present time.
Lazard is running the sales process for closely held Ascendis. Indicative bids ranging from roughly $350 million to $450 million have been received, with binding offers likely due by the end of July, reports the WSJ, noting that a sale is not guaranteed and the company could even be sold in pieces.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze